Thrombolytics LLC
Thrombolytics, LLC is a company dealing in intellectual property. Our primary role is to discover new and improved classes of anti-fibrinolytic agents and acquire the associated intellectual property rights. We are seeking a party to acquire these patent rights, with a goal of developing and marketing new drugs to treat bleeding disorders.
While the knowledge base concerning fibrinolytic mechanisms has vastly improved over the past few decades, virtually no change has occurred in the available options for anti-fibrinolytic pharmaceuticals. There are presently only two marketed compounds, tranexamic acid (TXA) and aminocaproic acid (ACA), commonly used to treat all varieties of bleeding by slowing down the breakdown of clots. While both compounds have been in use for over fifty years, they exhibit inferior biological activities by current standards, and are no longer protected by patents. Even so, the worldwide market for TXA is still around $400-$500 million USD.
Dr. Bakshy A. Chibber, retired Professor of Chemistry at Notre Dame and founder of Thrombolytics, LLC, recently discovered new and significantly improved anti-fibrinolytic compounds which are protected by a U.S. provisional patent application filed in 2014. Some of these compounds are constituted from natural human metabolic components, some are semi-synthetic, while others are entirely synthetic.
Among the compounds described in the pending patent application are two anti-fibrinolytic preclinical candidates which are similar structurally to the existing generic drugs, TXA and ACA. In fact, the sole difference between the two preclinical candidates and the generic compounds is a single functional group change. However, this seemingly minor change radically improves the efficacy of the drug candidates and, importantly, allows them to be considered favorably under the FDA’s guidelines for changes in an approved drug application.
For pharmaceutical companies that already have an FDA-approved application for any TXA- or ACA-containing formulation, acquisition of this patent provides a rapid path to FDA approval without having to go through long and expensive phased drug trials. As such, these preclinical compounds are particularly attractive candidates to replace the generic pharmaceuticals.
For more information, please contact:
Manoj Bakshi,Managing Member Thrombolytics LLC